Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
6.30
+0.08 (1.29%)
At close: Feb 11, 2026, 4:00 PM EST
6.34
+0.04 (0.63%)
After-hours: Feb 11, 2026, 4:00 PM EST
Kezar Life Sciences Employees
Kezar Life Sciences had 55 employees as of December 31, 2024. The number of employees decreased by 3 or -5.17% compared to the previous year.
Employees
55
Change (1Y)
-3
Growth (1Y)
-5.17%
Revenue / Employee
n/a
Profits / Employee
-$1,121,909
Market Cap
46.14M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 55 | -3 | -5.17% |
| Dec 31, 2023 | 58 | -26 | -30.95% |
| Dec 31, 2022 | 84 | 28 | 50.00% |
| Dec 31, 2021 | 56 | 9 | 19.15% |
| Dec 31, 2020 | 47 | 7 | 17.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 70 |
| LeonaBio | 26 |
| Plus Therapeutics | 21 |
| NeurAxis | 21 |
| ABVC BioPharma | 19 |
| TuHURA Biosciences | 19 |
| Lipocine | 16 |
| Atossa Therapeutics | 15 |
KZR News
- 4 weeks ago - Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis - Business Wire
- 3 months ago - Kezar Life Sciences Reports Third Quarter 2025 Financial Results - Business Wire
- 3 months ago - Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025 - Business Wire
- 4 months ago - Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives - Business Wire
- 5 months ago - Kezar Life Sciences to Participate in Two Upcoming Investor Conferences - Business Wire
- 6 months ago - Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 7 months ago - Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis - Business Wire
- 9 months ago - Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference - Business Wire